Literature DB >> 26324507

Heme Oxygenase-1 Is Not Decreased in Preeclamptic Placenta and Does Not Negatively Regulate Placental Soluble fms-Like Tyrosine Kinase-1 or Soluble Endoglin Secretion.

Stephen Tong1, Tu'uhevaha J Kaitu'u-Lino2, Kenji Onda2, Sally Beard2, Roxanne Hastie2, Natalie K Binder2, Cathy Cluver2, Laura Tuohey2, Clare Whitehead2, Fiona Brownfoot2, Manarangi De Silva2, Natalie J Hannan2.   

Abstract

Elevated placental release of the antiangiogenic factors, soluble fms-like tyrosine kinase-1 (sFlt-1) and soluble endoglin (sENG), is central to the pathophysiology of preeclampsia. It is widely accepted that heme oxygenase-1 (HO-1) is decreased in preeclamptic placenta and negatively regulates sFlt-1 and sENG production. We set out to verify these contentions. There was no difference in HO-1 mRNA or protein levels in preterm preeclamptic placentas (n=17) compared with gestationally matched controls (n=27). In silico analysis of microarray studies did not identify decreased placental HO-1 expression in preeclamptic placenta. Silencing HO-1 in primary trophoblasts did not affect sFlt-1 protein secretion after 24 or 48 hours. Silencing nuclear factor (erythroid-derived 2)-like 2 (transcription factor that upregulates HO-1) in trophoblasts also did not affect sFlt-1 secretion. Administering tin protoporphyrin IX dichloride (HO-1 inhibitor) or cobalt protoporphyrin (HO-1 inducer) into placental explants did not affect sFlt-1 or sENG secretion. Silencing HO-1 in 2 types of primary endothelial cells (human umbilical vein endothelial and uterine microvascular endothelial cells) significantly increased sFlt-1 secretion but not sENG secretion. However, HO-1 silencing selectively increased mRNA expression of sFlt-1 i13 (generically expressed sFlt-1 variant) but not of sFlt-1 e15a (sFlt-1 variant mainly expressed in placenta). Furthermore, adding tin protoporphyrin IX dichloride decreased sFlt-1, whereas adding HO-1 inducers (cobalt protoporphyrin, dimethyl fumarate, and rosiglitazone) either had no effect or increased sFlt-1 or sENG secretion (these trends are opposite to what is expected). We conclude that HO-1 expression is not decreased in preeclamptic placenta and HO-1 does not negatively regulate placental sFlt-1 and sENG secretion in placental or endothelial cells.
© 2015 American Heart Association, Inc.

Entities:  

Keywords:  FLT1 protein, human; heme oxygenase-1; placenta; preeclampsia; pregnancy

Mesh:

Substances:

Year:  2015        PMID: 26324507     DOI: 10.1161/HYPERTENSIONAHA.115.05847

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  13 in total

1.  Rosiglitazone augments antioxidant response in the human trophoblast and prevents apoptosis†.

Authors:  Hamid-Reza Kohan-Ghadr; Brian A Kilburn; Leena Kadam; Eugenia Johnson; Bradley L Kolb; Javier Rodriguez-Kovacs; Michael Hertz; D Randall Armant; Sascha Drewlo
Journal:  Biol Reprod       Date:  2019-02-01       Impact factor: 4.285

2.  The early developments of preeclampsia drugs.

Authors:  Maged M Costantine; Cande V Ananth
Journal:  Expert Opin Investig Drugs       Date:  2016-06-16       Impact factor: 6.206

Review 3.  Heme Oxygenases in Cardiovascular Health and Disease.

Authors:  Anita Ayer; Abolfazl Zarjou; Anupam Agarwal; Roland Stocker
Journal:  Physiol Rev       Date:  2016-10       Impact factor: 37.312

4.  Neurodevelopment at Age 10 Years of Children Born <28 Weeks With Fetal Growth Restriction.

Authors:  Steven J Korzeniewski; Elizabeth N Allred; Robert M Joseph; Tim Heeren; Karl C K Kuban; T Michael O'Shea; Alan Leviton
Journal:  Pediatrics       Date:  2017-10-13       Impact factor: 7.124

Review 5.  Resolution of inflammation pathways in preeclampsia-a narrative review.

Authors:  Luiza Oliveira Perucci; Mário Dias Corrêa; Luci Maria Dusse; Karina Braga Gomes; Lirlândia Pires Sousa
Journal:  Immunol Res       Date:  2017-08       Impact factor: 2.829

6.  Fetal sex and maternal postpartum depressive symptoms: findings from two prospective pregnancy cohorts.

Authors:  Whitney Cowell; Elena Colicino; Talia Askowitz; Farida Nentin; Rosalind J Wright
Journal:  Biol Sex Differ       Date:  2021-01-06       Impact factor: 5.027

7.  Effects of simvastatin, rosuvastatin and pravastatin on soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin (sENG) secretion from human umbilical vein endothelial cells, primary trophoblast cells and placenta.

Authors:  Fiona C Brownfoot; Stephen Tong; Natalie J Hannan; Roxanne Hastie; Ping Cannon; Tu'uhevaha J Kaitu'u-Lino
Journal:  BMC Pregnancy Childbirth       Date:  2016-05-20       Impact factor: 3.007

8.  Melatonin enhances antioxidant molecules in the placenta, reduces secretion of soluble fms-like tyrosine kinase 1 (sFLT) from primary trophoblast but does not rescue endothelial dysfunction: An evaluation of its potential to treat preeclampsia.

Authors:  Natalie J Hannan; Natalie K Binder; Sally Beard; Tuong-Vi Nguyen; Tu'uhevaha J Kaitu'u-Lino; Stephen Tong
Journal:  PLoS One       Date:  2018-04-11       Impact factor: 3.240

9.  Overexpressed HO-1 is associated with reduced STAT3 activation in preeclampsia placenta and inhibits STAT3 phosphorylation in placental JEG-3 cells under hypoxia.

Authors:  Hong-Mei Qu; Li-Ping Qu; Xiao-Yan Li; Xian-Zhen Pan
Journal:  Arch Med Sci       Date:  2016-10-26       Impact factor: 3.318

10.  Circulating Heme Oxygenase-1: Not a Predictor of Preeclampsia but Highly Expressed in Pregnant Women Who Subsequently Develop Severe Preeclampsia.

Authors:  Valéria C Sandrim; Mayara Caldeira-Dias; Heloisa Bettiol; Marco Antonio Barbieri; Viviane Cunha Cardoso; Ricardo Carvalho Cavalli
Journal:  Oxid Med Cell Longev       Date:  2018-09-30       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.